# Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

> **NCT06186401** · PHASE1 · RECRUITING · sponsor: **Hideho Okada, MD, PhD** · enrollment: 20 (estimated)

## Conditions studied

- EGFR Gene Mutation
- Glioblastoma
- MGMT-Unmethylated Glioblastoma
- Recurrent Glioblastoma

## Interventions

- **BIOLOGICAL:** E-SYNC T Cells
- **DRUG:** Cyclophosphamide (non-investigational)
- **DRUG:** Fludarabine (non-investigational)
- **PROCEDURE:** Leukapheresis
- **PROCEDURE:** Surgical resection

## Key facts

- **NCT ID:** NCT06186401
- **Lead sponsor:** Hideho Okada, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-30
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06186401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06186401, "Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06186401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*